| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK PHARMS INC | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(7 months ago) | |
| US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2024
(a month from now) | |
| US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(2 years ago) | |
| US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(4 years from now) | |
| US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(6 years from now) | |
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(13 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(13 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(13 years from now) | |
Nuzyra is owned by Paratek Pharms Inc.
Nuzyra contains Omadacycline Tosylate.
Nuzyra has a total of 11 drug patents out of which 2 drug patents have expired.
Expired drug patents of Nuzyra are:
- US9365500
- US7326696
Nuzyra was authorised for market use on 02 October, 2018.
Nuzyra is available in powder;intravenous, tablet;oral dosage forms.
Nuzyra can be used as treatment of bacterial skin and skin structure infections, treatment of community acquired bacterial pneumonia, treatment of subjects having bacterial skin or skin structure infection, treatment of bacterial skin and skin structure infection.
Drug patent challenges can be filed against Nuzyra from 03 October, 2027.
The generics of Nuzyra are possible to be released after 31 October, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of bacterial skin and skin structure infection; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...
Dosage: POWDER;INTRAVENOUS; TABLET;ORAL
NUZYRA family patents
